Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Diet Rich in N-3 Polyunsaturated Fatty Acids in Renal Transplant Recipients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01872455
Recruitment Status : Completed
First Posted : June 7, 2013
Last Update Posted : June 7, 2013
Sponsor:
Information provided by (Responsible Party):
Eleonora Riccio, Federico II University

Brief Summary:
n-3 Polyunsaturated fatty acids (PUFAs) supplementation reduces systemic inflammation and improves renal and cardiovascular prognosis in kidney transplant recipients. A good patient compliance is often difficult to obtain because bad tasting fish oils are used as n-3 PUFA source. Therefore, we explored whether n-3 beneficial effects can be obtained by administering a diet based on n-3 rich foods.

Condition or disease Intervention/treatment Phase
Kidney Transplantation Dietary Supplement: n-3 rich diet Dietary Supplement: Usual diet Phase 4

Detailed Description:

An emerging concept in clinical nutrition is that dietary interventions may improve the course of systemic inflammatory disorders like rheumatoid arthritis and psoriasis. Most of this effect depends on the ability of polyunsaturated fatty acids (PUFAs) to modulate immune and inflammatory responses. Two main families of PUFAs exist in human tissues: n-3 PUFAs that have a marked anti-inflammatory activity and n-6 PUFAs that, conversely, promote inflammation. Multiple mechanisms account for the modulation of the inflammatory response by PUFAs. Recent lipidemic studies have added new mediators like lipoxins to the list of PUFA metabolites controlling inflammation that classically included only pro-inflammatory or anti-inflammatory prostaglandins like PGE2 and PGE3, respectively. The concerted activity of these mediators may determine a decreased recruitment of inflammatory cells in target tissues, with a lower release of pro-inflammatory cytokines like Interleukin-6 (IL-6) and necrosis tumor factor-α (TNF), and their higher apoptosis rate.

n-3 PUFAs include α-linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), whereas linoleic acid (LA) and arachidonic acid (AA) are the main n-6 PUFAs. ALA and LA are both essential fatty acids because they cannot be synthetized in the human body and have to be assumed with the diet. They are the precursors of downstream immunomodulatory long-chain fatty acids: LA is converted to AA that has marked a pro-inflammatory activity and is further transformed in pro-inflammatory eicosanoids (PGE2) and leukotrienes. On the contrary, ALA is converted to EPA and DHA, the precursors of anti-inflammatory prostaglandins (PGE3) and inhibits the production of AA and the synthesis of thromboxane. Importantly, the amount of ALA converted to EPA and DHA in humans is usually low which makes also these fatty acids essential. The current western diet is poor of n-3 PUFAs and this suggests that n-3 PUFAs-dependent endogenous anti-inflammatory mechanisms could be potentiated by simultaneously increasing n-3 PUFA intake and lowering the n-6/n-3 ratio. Indeed, a high n-6/n-3 ratio is associated to a worse clinical course in cardiovascular, inflammatory and autoimmune diseases. With the rationale of increasing n-3 PUFAs intake and of lowering the n-6/n-3 ratio, n-3 PUFAs supplementations like fish oil have been given with favorable clinical results to patients affected by different chronic inflammatory diseases including rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Fish oil, however, has a low palatability and this may cause a low patients' compliance during prolonged therapy. Since seafood, and several fruits and vegetables have a high content of n-3 PUFAs, dietary regimens based on these specific foods are expected to increase n-3 PUFAs intake., thus representing an attractive alternative to the administration of exogenous fish oils products in therapeutic programs aimed to exploit the beneficial n-3 PUFAs effects in systemic inflammatory disorders.

Therefore, the investigators explored the effect of a diet based on food with a high n-3 and low n-6 PUFAs content in long-term kidney transplant recipients. These patients could benefit from an increase in n-3 PUFAs intake because a persistent systemic inflammatory status occurs after kidney transplantation, that greatly contributes to the development of cardiovascular diseases and of chronic allograft dysfunction. Previous studies showed that dietary administration of n-3 increases graft survival in different animal models of organ transplantation, whereas n-6 PUFAs had opposite effects. Recently, the efficacy of n-3 PUFAs supplementation with canola oil in decreasing systemic inflammation and in lowering the incidence of rejections was demonstrated also in humans.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: EFFECTS OF A DIET RICH IN N-3 POLYUNSATURATED FATTY ACIDS ON SYSTEMIC INFLAMMATION IN RENAL TRANSPLANT RECIPIENTS
Study Start Date : January 2010
Actual Primary Completion Date : January 2012
Actual Study Completion Date : January 2012

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Group CON
patients who refused to assume the n-3 rich diet and continued their usual diet
Dietary Supplement: Usual diet
Usual diet of the patients

Experimental: Group DIET
the patients assumed n-3 rich diet: Patients of the DIET group were requested to follow a diet specifically designed to increase the intake of n-3 PUFAs and to decrease the ratio n-6/n-3 by using natural foods.
Dietary Supplement: n-3 rich diet
This dietary plan included seafood (salmon, sardines, herrings, and bluefish) and specific fruits and vegetables (oranges, strawberries, cherries, bananas, courgettes, artichokes, mushrooms, cauliflowers and pumpkins). Olive oil, rich in monounsaturated fats, was also included in the dietary plan. Patients were encouraged to use n-3 rich margarine as additional source of fatty acids. According to the data of the manufacturer, the fatty acid composition of this margarine was 3.4 mg of n-3 and 7.8 mg of n-6 per 100 g of weight. To keep n-6 PUFA intake low, patients were also requested to eat less eggs, meat, whole grains and cereals. All the components of the diet were fresh foods, with the exception of salmon and herrings that could also be preserved. Because no change in body weight was requested, patients maintained the same energy and protein intake of the diet that they assumed before entering the study.




Primary Outcome Measures :
  1. Nutritional assessment [ Time Frame: 6 months ]
    Anthropometric, body composition, biochemical, dietary and inflammatory parameters were recorded in all patients participating to the study, at baseline and three and six months after the start of the protocol. Body mass index (BMI) was calculated as the ratio body weight/height2 (in kg/m2) whereas bioelectrical impedance analysis (BIA) was used to evaluate body composition. Resistance and reactance were measured with a single-frequency 50 kHz bioelectrical impedance analyser, according to the standard tetrapolar technique and using the software provided by the manufacturer.

  2. Inflammatory markers [ Time Frame: 6 months of diet ]
    Biochemical nutritional markers included standard blood chemicals like serum albumin, urea nitrogen, glycemia and electrolytes, whereas fibrinogen, ferritin, Interleukin-6 (IL-6), and high sensitivity C Reactive Protein (hs-CRP) were assessed as markers of inflammation. IL-6 messenger ribonucleic acid (mRNA) levels were also determined in peripheral blood mononuclear cells (PBMC) at baseline and three and six months after beginning of the study.

  3. renal function [ Time Frame: 6 months of diet ]
    Renal allograft function was evaluated by Glomerular Filtration Rate (GFR), proteinuria, and microalbuminuria; GFR was calculated by the 4-variable Modification of Diet in Renal Disease (MDRD) equation (eGFR). Urinary determinations were carried out on samples collected for 24 hours.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • age >18 years,
  • transplant vintage >12 months,
  • a preserved and stable renal function (eGFR>20 ml/min),
  • plasma urea concentration <150 mg/dl,
  • plasma albumin concentration >3.8 g/dl,
  • and a stable protein and salt intake (±15%) in the last two visits

Exclusion Criteria:

  • malignancies,
  • autoimmune diseases
  • and severe infectious diseases in the last three months before the enrollment visit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01872455


Locations
Layout table for location information
Italy
federico II Univeristy
Naples, Italy, 80131
Sponsors and Collaborators
Federico II University

Layout table for additonal information
Responsible Party: Eleonora Riccio, md, Federico II University
ClinicalTrials.gov Identifier: NCT01872455     History of Changes
Other Study ID Numbers: TX13
TX ( Other Identifier: Ethic commettee )
First Posted: June 7, 2013    Key Record Dates
Last Update Posted: June 7, 2013
Last Verified: January 2012